CMAB008 is a monoclonal antibody developed as a biosimilar to infliximab (Remicade
The population pharmacokinetic model was developed on the basis of intensive pharmacokinetic data from a phase 1 study in healthy male subjects and combined intensive and sparse pharmacokinetic data from a phase 3 study in patients with RA.
A two-compartment model with first-order elimination adequately described CMAB008 and Remicade
The pharmacokinetic characteristics were similar between CMAB008 and Remicade
ClinicalTrials.gov identifiers NCT04779892, NCT03478111.